MIYAZAKI, T. Tolvaptan, an orally active vasopressin V2-receptor antagonist-pharmacology and clinical trials. Cardiovasc Drug Rev. 2007, 25, 1, 1-13
SCHRIER, RW. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006, 355, 20, 2099-2112
GHEORGHIADE, M. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure : results from a double-blind, randomized trial. Circulation. 2003, 107, 21, 2690-2696
GHEORGHIADE, M. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure : the EVEREST Clinical Status Trials. JAMA. 2007, 297, 12, 1332-1343
KONSTAM, MA. Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVER-EST Outcome Trial. JAMA. 2007, 297, 12, 1319-1331